Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Acelrx Pharmaceutica (NQ: ACRX )

0.7286 -0.0346 (-4.53%)
Streaming Delayed Price Updated: 4:00 PM EST, Dec 8, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Acelrx Pharmaceutica

< Previous 1 2 3 4 5 6 Next >
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. (ACRX)
From Law Offices of Howard G. Smith
Via Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of AcelRx Pharmaceuticals, Inc. (ACRX) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
SHAREHOLDER ALERT: Robbins LLP Announces that AcelRX Pharmaceuticals, Inc. (ACRX) is Being Sued for Misleading Shareholders
From Robbins LLP
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces the Filing of a Securities Class Action on Behalf of AcelRx Pharmaceuticals, Inc. (ACRX) Investors
From Glancy Prongay & Murray LLP
Via Business Wire
SHAREHOLDER ACTION REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces the Filing of a Securities Class Action on Behalf of AcelRx Pharmaceuticals, Inc. (ACRX) Investors
From Law Offices of Howard G. Smith
Via Business Wire
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of AcelRx Pharmaceuticals, Inc. (ACRX) on Behalf of Investors
From Glancy Prongay & Murray LLP
Via Business Wire
The Law Offices of Frank R. Cruz Announces Investigation of AcelRx Pharmaceuticals, Inc. (ACRX) on Behalf of Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
SHAREHOLDER ACTION ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against AcelRx Pharmaceuticals, Inc. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm
From The Schall Law Firm
Via Business Wire
INVESTOR ALERT: Law Offices of Howard G. Smith Announces Investigation of AcelRx Pharmaceuticals, Inc. (ACRX) on Behalf of Investors
From Law Offices of Howard G. Smith
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Intraday Session
Gainers Aethlon Medical (NASDAQ:AEMD) shares moved upwards by 347.96% to $9.9 during Wednesday's regular session. As of 12:30 EST, Aethlon Medical's stock is... 
Via Benzinga
EQUITY ALERT: ROSEN, A TOP RANKED LAW FIRM, Encourages AcelRx Pharmaceuticals, Inc. Investors with Losses to Secure Counsel Before Important Deadline – ACRX
From The Rosen Law Firm, P.A.
Via Business Wire
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Gainers Aethlon Medical (NASDAQ:AEMD) stock rose 248.41% to $7.7 during Wednesday's pre-market session. The market value of their outstanding shares is at $93.4... 
Via Benzinga
ACELRX PHARMACEUTICALS ALERT: Bragar Eagel & Squire, P.C. Announces That a Class Action Lawsuit Has Been Filed Against AcelRx Pharmaceuticals, Inc. and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire, P.C.
Via Business Wire
AcelRx Pharmaceuticals: Q1 Earnings Insights
Shares of AcelRx Pharmaceuticals (NASDAQ:ACRX) decreased in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share rose 60.00% year... 
Via Benzinga
The Week Ahead In Biotech: Sanofi, Bristol-Myers Squibb Await FDA Decisions, Earnings News Flow Tapers Off
Biotech stocks had a volatile ride in the week ended May 14, with stocks moving lower for much of the week before coming back up strongly in the final session. Some of the weakness may be traced back... 
Via Talk Markets
Exposures Product Safety
The Week Ahead In Biotech: Sanofi, Bristol-Myers Squibb Await FDA Decisions, Earnings News Flow Tapers Off
Biotech stocks had a volatile ride in the week ended May 14, with stocks moving broadly lower for much of the week before coming back up strongly in the final session. Some of the... 
Via Benzinga
Exposures Product Safety
Earnings Scheduled For May 17, 2021
Companies Reporting Before The Bell • Hycroft Mining Holding (NASDAQ:HYMC) is estimated to report earnings for its first quarter. • U.S. Well Services (NASDAQ:... 
Via Benzinga
AcelRx's Dsuvia Shows Reduction In Postoperative Opioids Compared To Control Group
AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) has announced a poster presentation at the Annual Regional Anesthesiology and Acute Pain Medicine Meeting reviewing the... 
Via Benzinga
58 Biggest Movers From Yesterday
Gainers Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) shares jumped 104.2% to close at $8.70 on Monday after the company announced the full details of its Phase 2 trial... 
Via Benzinga
38 Stocks Moving In Monday's Mid-Day Session
Gainers Reviva Pharmaceuticals Holdings, Inc. (NASDAQ: RVPH) surged 46.9% to $6.25 after the company announced the full details of its Phase 2 trial evaluating its lead drug... 
Via Benzinga
21 Stocks Moving in Monday's Pre-Market Session
Gainers Ocugen, Inc. (NASDAQ: OCGN) shares rose 20.6% to $11.61 in pre-market trading. Ocugen’s COVID-19 vaccine partner, India-based Bharat Biotech International Ltd.,... 
Via Benzinga
Exposures COVID-19
12 Health Care Stocks Moving In Thursday's After-Market Session
Gainers DiaMedica Therapeutics (NASDAQ:DMAC) shares increased by 6.17% to $9.98 during Thursday's after-market session. DiaMedica Therapeutics's trading volume hit 12.0K... 
Via Benzinga
AcelRx To Test Dsuvia In Patients On Buprenorphine Requiring A Surgical Procedure
AcelRx Pharmaceuticals Inc (NASDAQ: ACRX) has announced an investigator-initiated study to assess the perioperative use of Dsuvia (sufentanil sublingual... 
Via Benzinga
< Previous 1 2 3 4 5 6 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.